Clinical trial
Levosimendan Pretreatment for Weaning Patients From Cardio-Pulmonary Bypass
NCT00130871 · Orion Corporation, Orion Pharma, Industry · Completed
Key facts
| NCT number | NCT00130871 |
|---|---|
| Title | Levosimendan Pretreatment for Weaning Patients From Cardio-Pulmonary Bypass |
| Official title | Impact of Levosimendan Pretreatment on Weaning From Cardiopulmonary Bypass (CPB) in Patients With Diminished Left Ventricular Function Before Coronary Artery Bypass Grafting (CABG) |
| Lead sponsor | Orion Corporation, Orion Pharma, Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Coronary Heart Disease |
| Intervention type | Drug |
| Interventions | levosimendan |
| Enrollment | 60 |
| Start date | Jan 1, 2004 |
| Completion | Jan 1, 2006 |
| First posted | Aug 16, 2005 |
| Last update posted | Feb 21, 2007 |
| Countries | Finland |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: